HPLC is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-08-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
=== Brand names === Tranexamic acid is marketed in the US and Australia in tablet form as Lysteda and in Australia, Sweden and Jordan it is marketed in an IV form and tablet form as Cyklokapron, in the UK and Sweden as Cyclo-F. In the UK it is also marketed as Femstrual, in Asia as Transcam, in Bangladesh as Intrax & Tracid, in India as Pause, in Pakistan as Transamin, in Indonesia as Kalnex, in South America as Espercil, in Japan as Nicolda, in France, Poland, Belgium, and Romania as Exacyl and in Egypt as Kapron. In the Philippines, its capsule form is marketed as Hemostan and in Israel as Hexakapron.
Although councils had already suffered deep cuts under Labour in the 1970s, Heseltine was under pressure from Thatcher and from Conservative MPs and newspapers to cut more. Heseltine's initial suggestion, that councils who wanted to increase the rates be forced to submit to re-election, was rejected by the Cabinet, in favour of a proposal that such increases be put to referendum (in Coventry, voters had recently voted by over 7:1 for spending cuts rather than a supplementary rate increase). This proposal in turn was attacked by Conservative backbenchers, both as an infringement of council freedom and a risky precedent for national taxation, both in the Environment Committee and in the debate on a bill which Heseltine introduced and had to withdraw. Heseltine then banned supplementary rates and imposed stiffer sanctions on overspending councils. Thatcher's 1974 pledge to abolish the rates and replace them with a new form of local government funding was still in force. However, the 1979 manifesto made clear that income tax cuts took priority over rates reform. Thatcher also blocked the upward revaluation of property rating values in 1982. A review of rates reform was begun in 1981, in which his junior minister Tom King personally spoke to every single backbench Conservative MP to canvass opinion about the various options. A Green Paper was produced in December 1981, recommending that no single alternative to the rates suggested itself.
A protein kinase is a kinase which selectively modifies other proteins by covalently adding phosphates to them (phosphorylation) as opposed to kinases which modify lipids, carbohydrates, or other molecules. Phosphorylation usually results in a functional change of the target protein (substrate) by changing enzyme activity, cellular location, or association with other proteins. The human genome contains about 500 protein kinase genes and they constitute about 2% of all human genes. There are two main types of protein kinase. The great majority are serine/threonine kinases, which phosphorylate the hydroxyl groups of serines and threonines in their targets. Most of the others are tyrosine kinases, although additional types exist. Protein kinases are also found in bacteria and plants. Up to 30% of all human proteins may be modified by kinase activity, and kinases are known to regulate the majority of cellular pathways, especially those involved in signal transduction.
== History == The concept of electrostatically trapping ions in an orbit around a central spindle was developed by Kenneth Hay Kingdon in the early 1920s. The Kingdon trap consists of a thin central wire and an outer cylindrical electrode. A static applied voltage results in a radial logarithmic potential between the electrodes. In 1981, Knight introduced a modified outer electrode that included an axial quadrupole term that confines the ions on the trap axis. Neither the Kingdon nor the Knight configurations were reported to produce mass spectra. In 1986, Professor Yuri Konstantinovich Golikov in USSR developed theory of ion motion in quadro-logarithmic potential, and filed for patents in USSR for its use in a time-of-flight analyzer. Golikov, leading a team at the St. Petersburg State Pedagogical University's Radiophysics Faculty, laid the theoretical groundwork for Orbitrap technology as one of inventors in USSR Inventor's certificate No. 1247973 in 1986. Golikov later remarked "Based on my ideas, analytical instruments with record parameters were built, but unfortunately not in Russia, but abroad." Contrary to popular belief, Alexander Makarov is not the original inventor of quadro-logarithmic potential which was known since 1950s. Reflecting on his early interaction with Golikov, Alexander Makarov recalled, "As a fifth-year student at MIPT, I entered one of the numerous rooms at the Polytechnic Institute, where I was met by Yuri Konstantinovich Golikov.
=== Drug design of RXPA 380 === RXPA380 was the first inhibitor that was highly selective of the C-domain of ACE, it has the formula Phe-Phe-Pro-Trp. The development of this compound was built on researches that showed that some bradykinin-potentiating peptides showed selectivity for the C-domain and all had several prolines in their structure. These observations lead the researchers to synthesize phosphinic peptides containing a proline residue in the P1’ position and evaluating these compounds led to the discovery of RXPA380. To study the roles of the residues on RXPA380 the researchers made 7 analogues of RXPA380. All of the compounds made were obtained as a mixture of either 2 or 4 diastereoisomers but all of them were easily resolved and only one of them was potent. This is consistent with the initial modeling studies of RXPA380 which showed that only one diastereomer could accommodate in the active site of germinal ACE. Analogues where pseudo-proline or tryptophan residues had been substituted showed less selectivity than RXPA380. This is probably because these two analogues have more potency toward the N-domain than RXPA380 does. Substituting both of these residues gives great potency but none selectivity. This shows that pseudo-proline and tryptophan residues accommodate well in the C-domain but not in the N-domain. Two more analogues with both pseudo-proline and tryptophan but missing the pseudo-phenylalanine residue in P1 position showed low potency for N-domain, similar to RXPA380.
Sources: en.wikipedia.org
=== Nonprofit organizations === In the 2020s, several nonprofit organizations have emerged in the U.S. and Europe to focus on AI safety and related public policies, including the Alliance for Secure AI, Future of Life Institute, and Public First Action. Such groups often function as Silicon Valley watchdogs and advocate for specific federal, state, or local regulations. They also compete with industry groups such as Leading the Future, which advocate for the deregulation of AI companies.
Rotating cell‑based ligand binding assay using radioactivity or fluorescence, is a recent method that measures molecular interactions in living cells in real-time. This method allows the characterization of the binding mechanism, as well as Kd, kon and koff. This principle is being applied in several studies, mainly with protein ligands and living mammalian cells. An alternative technology to measure protein interactions directly on cells is Real-Time Interaction Cytometry (RT-IC). In this technology, the living or fixed cells are physically retained on the surface of biosensor chips using biocompatible and flow-permeable polymer traps. Binding and unbinding of automatically injected labeled analytes is measured by time-resolved fluorescence detection. Single colour reflectometry (SCORE) is a label-free technology for measuring all kinds of biomolecular interactions in real-time. Similar to BLI, it exploits interference effects at thin layers. However, it does not need a spectral resolution but rather uses monochromatic light. Thus, it is possible to analyse not only a single interaction but high-density arrays with up to 10,000 interactions per cm2. switchSENSE is a technology based on DNA nanolevers on a chip surface. A fluorescent dye as well as the unlabeled ligand are attached to this nanolever. Upon binding of an analyte to the ligand, the real-time kinetic rates (kon, koff) can be measured as changes in fluorescence intensity and the Kd can be derived.
Significance of research: The summary of the POPC simulations described above shows that the POPC system's initial area per lipid value was initially .65 ± .01 but it increases by more than 70% to 1.09 ± .03 at 10 mol% of ethanol which indicates the membrane begins to swell and expand as ethanol permeates through its exterior region. Due to the expansion of the membrane, the membrane thickness decreases from 3.83 ± .06 to 2.92 ± .05 which relates to the distance between the phosphorus atoms on opposite sides of the membrane. The study also supports the fact that ethanol prefers to bond just below the hydrophilic region of the phospholipids near the phosphate groups. The location of the ethanol creates a strong hydrogen bond between the water molecules. The results are depicted in the simulations and supported by mass density profiles as well. The mass density profiles show the location of the POPC lipids, water, and ethanol relevant to the hydrophobic core of the membrane and the concentration of ethanol. The mass density of ethanol increases as the concentration increases which indicates ethanol is moving towards the hydrophobic core of the membrane. The membrane becomes partially destroyed. The simulations also support that the interior of the membrane starts to become more hydrophilic due to the presence of water molecules in the interior region once the membrane is partially destroyed. The presence of ethanol also induced the formation of non-lamellar phases (non-bilayer) within the interior region (hydrophobic cored) of the phospholipid membrane.
=== Impact of El Mencho's influence through his marriage === Following El Mencho's death in February 2026, it was reported that El Mencho had actually gained influence in the CJNG through his marriage to Rosalinda González Valencia. Despite the influence he obtained through his marriage to Valencia, he was acknowledged to have separated from her in 2018, and was even involved with a different romantic partner at the time of his death in February 2026. Nevertheless, El Mencho's stepson was regarded to be his "de facto second-in-command" by the time of his death. As of result of his marriage to Valencia, who is also the niece of Milenio Cartel founder Armando Valencia Cornelio, alias “El Maradona,” El Mencho was able to recruit numerous former Mileno Cartel members into the CJNG. El Mencho's stepson, Juan Carlos Valencia González, would even succeed him as head of the CJNG by March 2026. Juan is acknowledged to be Valencia's son from her previous marriage to Cornelio.
Sources: en.wikipedia.org
The Susceptible-Infectious-Recovered-Deceased model differentiates between Recovered (meaning specifically individuals having survived the disease and now immune) and Deceased. The SIRD model has semi analytical solutions based on the four parts method. This model uses the following system of differential equations:
== Education == Chandan Sen earned his Bachelor of Science degree (Honors in Physiology) in 1987 and his Master of Science in Human Physiology in 1990 from the Rajabazar Science College at Calcutta University. He subsequently moved to Finland for advanced studies and received his Ph.D. in Physiology in 1994 from the School of Medicine at the University of Eastern Finland (Kuopio Campus). In January 1995, Sen joined the University of California, Berkeley for postdoctoral research in the Department of Molecular and Cell Biology, focusing on redox signaling (1995–1996). In 1997, Sen accepted his first faculty appointment at the Lawrence Berkeley National Laboratory in Berkeley, California.
No animal species is known to be immune to the acute toxic effects of aflatoxins. Adult humans have a high tolerance for aflatoxin exposure and rarely succumb to acute aflatoxicosis, but children are particularly affected, and their exposure can lead to stunted growth and delayed development, in addition to all the symptoms mentioned below. High-level aflatoxin exposure produces an acute hepatic necrosis (acute aflatoxicosis), resulting later in cirrhosis or carcinoma of the liver. Acute liver failure is made manifest by bleeding, edema, alteration in digestion, changes to the absorption and/or metabolism of nutrients, and mental changes and/or coma. Chronic, subclinical exposure does not lead to symptoms as dramatic as acute aflatoxicosis. Chronic exposure increases the risk of developing liver and gallbladder cancer, as aflatoxin metabolites may intercalate into DNA and alkylate the bases through its epoxide moiety. This is thought to cause mutations in the p53 gene, an important gene in preventing cell cycle progression when there are DNA mutations, or signaling apoptosis (programmed cell death). These mutations seem to affect some base pair locations more than others; for example, the third base of codon 249 of the p53 gene appears to be more susceptible to aflatoxin-mediated mutations than nearby bases. As with other DNA-alkylating agents, Aflatoxin B1 can cause immune suppression, and exposure to it is associated with an increased viral load in HIV positive individuals.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.